---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-041660"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:44:34.054924+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q2 revenue $20.7M (+167% YoY); raises FY2021 guidance to $90-95M

## Summary
- Revenue $20.7M, up 167% from $7.7M in Q2 2020; gross margin improved to 80.9% from 73.1%.
- Net loss of ($5.1M) or ($0.10) per share, compared to ($2.1M) loss a year ago.
- Cash and equivalents $119.6M, including $107.6M from April 2021 IPO.
- FY2021 revenue guidance raised to $90-95M (57-65% growth) from prior $87-92M.
- ALIGN3D clinical study shows positive radiographic and patient-reported outcomes from 6 weeks to 12 months.

## SEC filing metadata
- accession: 0001564590-21-041660
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000156459021041660/0001564590-21-041660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000156459021041660/tmci-8k_20210805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-041660
- JSON: https://secwatch.observer/filing/0001564590-21-041660.json
- Plain text: https://secwatch.observer/filing/0001564590-21-041660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.